Hikma Pharmaceuticals Plc Total Voting Rights (5557V)
December 16 2013 - 2:00AM
UK Regulatory
TIDMHIK
RNS Number : 5557V
Hikma Pharmaceuticals Plc
16 December 2013
Hikma Pharmaceuticals PLC
Voting Rights and Capital
LONDON, 16 December 2013, Hikma Pharmaceuticals PLC (LSE: HIK)
(NasdaqDubai: HIK) notifies the market that its capital consists of
197,967,328 ordinary shares with voting rights. There are 77,000
shares held in treasury (previously 210,000 of which 133,000 have
been used to satisfy option awards that have been exercised), which
do not carry voting rights and have been excluded from the above
figure.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, Hikma Pharmaceuticals PLC under the FCA's Disclosure and
Transparency Rules.
- ENDS -
Enquiries
Hikma Pharmaceuticals
PLC
Peter Speirs
Company Secretary +44 20 7399 2760
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2012, Hikma achieved
revenues of $1,108.7 million and profit attributable to
shareholders of $100.3 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVREAKADFSKDFFF
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024